Latest News from: Georgetown Lombardi Comprehensive Cancer Center

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 85
Newswise: Indoor Tanning May Be an Addiction Abetted by Both Genetic and Psychiatric Factors
  • Embargo expired:
    11-Jun-2019 11:00 AM EDT

Article ID: 714203

Indoor Tanning May Be an Addiction Abetted by Both Genetic and Psychiatric Factors

Georgetown Lombardi Comprehensive Cancer Center

A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity, important to the brain’s pleasure and reward system, appear to influence an addiction to indoor tanning in young, white non-Hispanic women.

Released:
11-Jun-2019 6:05 AM EDT
Newswise: Labels of U.S. Probiotic Products Lacking, Researchers Find
  • Embargo expired:
    4-Jun-2019 12:00 PM EDT

Article ID: 713796

Labels of U.S. Probiotic Products Lacking, Researchers Find

Georgetown Lombardi Comprehensive Cancer Center

When it comes to buying probiotics, most product labels do not give consumers enough information to make an informed decision, according to a research team led by Georgetown University Medical Center.

Released:
3-Jun-2019 4:50 AM EDT

Article ID: 713458

Patient Groups Untested in Cancer Immunotherapy Trials Found to Also Benefit

Georgetown Lombardi Comprehensive Cancer Center

Cancer patients previously excluded and underrepresented in immunotherapy clinical trials, such as African Americans and patients with HIV or viral hepatitis, actually benefit at the same rate as patients tested in the clinical trials, according to a Georgetown-led study to be presented at the 2019 ASCO Annual Meeting in Chicago.

Released:
30-May-2019 5:00 AM EDT

Article ID: 713481

Significant “Knowledge Gap” Exists in Use of Genetic Testing to Decide Cancer Treatment

Georgetown Lombardi Comprehensive Cancer Center

A survey conducted by Georgetown investigators found a significant knowledge and practice gap among community oncologists in the understanding and usage of genetic testing in determining patients' treatment plans and potential clinical trial outcomes.

Released:
30-May-2019 5:00 AM EDT
Newswise: Use of Genetic Testing in Women Diagnosed with Breast Cancer Decreases Cost of Care Nationwide
  • Embargo expired:
    24-Apr-2019 12:05 AM EDT

Article ID: 711607

Use of Genetic Testing in Women Diagnosed with Breast Cancer Decreases Cost of Care Nationwide

Georgetown Lombardi Comprehensive Cancer Center

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the first year). The study by Georgetown Lombardi Comprehensive Cancer Center and National Cancer Institute researchers was published April 24, in JNCI.

Released:
19-Apr-2019 10:30 AM EDT
  • Embargo expired:
    16-Apr-2019 12:05 PM EDT

Article ID: 711277

Large Federal Program Aimed at Providing Better Health Care Underfunds Primary Care

Georgetown Lombardi Comprehensive Cancer Center

Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the U.S. receive treatment.

Released:
14-Apr-2019 5:05 PM EDT
Newswise: Rare but Important Gene Target Found in Many Tumor Types, Suggesting New Therapy Possible
  • Embargo expired:
    15-Apr-2019 10:00 AM EDT

Article ID: 711238

Rare but Important Gene Target Found in Many Tumor Types, Suggesting New Therapy Possible

Georgetown Lombardi Comprehensive Cancer Center

A consortium of researchers led by Georgetown Lombardi Comprehensive Cancer Center investigators have completed the largest analysis of a new gene fusion they believe is responsible for development of a wide spectrum of cancer types.

Released:
12-Apr-2019 2:00 PM EDT
Newswise: @LombardiCancer-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer

Article ID: 709672

@LombardiCancer-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer

Georgetown Lombardi Comprehensive Cancer Center

The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriq®, Genentech) in combination with chemotherapy (carboplatin and etoposide) for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for those with the deadly disease.

Released:
18-Mar-2019 8:05 PM EDT

Showing results

110 of 85

Chat now!